Please login to the form below

Not currently logged in
Email:
Password:

Joachim Hasenmaier joins Boehringer’s board in senior shake-up

Company also appoints new board division of biopharmaceuticals and operations to reflect increased focus on biosimilars

Joachim Hasenmaier - BoehringerBoehringer Ingelheim has appointed Dr Joachim Hasenmaier (pictured) to its board of managing directors to head both consumer and animal health in a series of changes at the top for the German pharma company.

Dr Hasenmaier, who assumes his new role from October 1, 2012, has been with Boehringer since 2001, serving initially as divisional head, animal health, before taking over as regional business manager for Northern Europe and Canada in 2011.

“Joachim Hasenmaier's appointment is the outcome of a long term human resource strategy,” said Christian Boehringer, chair of the company's shareholders' committee.

“Recognising the special focus of animal health and the consumer healthcare business on the end-customer, it is meaningful to combine responsibilities in one board division.”

In addition, Professor Wolfram Carius, previously responsible for the board division of human resources and operations, will take charge of the new board division of biopharmaceuticals and operations to reflect Boehringer's increased focus on biosimilars.

Board chair Professor Andreas Barner will take over responsibilities for human resources as well as remaining board member for research & development and medicine.

The finance board division has also now been “distinctly separated” from the rest of the board divisions, with responsibility to remain with Hubertus von Baumbach.

Engelbert Tjeenk-Willink also stays in charge of Boehringer's prescriptions medicine business.

10th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics